Patients will be excluded if any of the following criteria are met: 1. The subject is a female who is breastfeeding or pregnant. 2. Known hypersensitivity to EB05 or its excipients. 3. In the opinion of the investigator, death is imminent and inevitable within the next 48 - 72 hours, irrespective of the provision of treatment. 4. Active participation in other immunomodulator or immunosuppressant drug clinical trials. participation in COVID-19 antiviral, anticoagulant and convalescent plasma trials may be permitted, however, the decision to enroll a patient who is participating in other clinical trials will be dealt with on a case by case basis. 5. Treatment with immunomodulator or immunosuppressant drugs, including but not limited to IL-6 inhibitors, TNF inhibitors, antiIL-1 agents, and JAK inhibitors within 5 half-lives or 30 days (whichever is longer) before randomization. (Note treatment with immunomodulator or immunosuppressant drugs, such as corticosteroids, as part of SOC, is permitted). 6. Known other clinical conditions that contraindicate EB05 and cannot be treated or solved according to the judgement of the clinician.

Patients will be excluded if any of the following criteria are met: 1. The subject is a female who is breastfeeding or pregnant. 2. Known hypersensitivity to EB05 or its excipients. 3. In the opinion of the investigator, death is imminent and inevitable within the next 48 - 72 hours, irrespective of the provision of treatment. 4. Active participation in other immunomodulator or immunosuppressant drug clinical trials. participation in COVID-19 antiviral, anticoagulant and convalescent plasma trials may be permitted, however, the decision to enroll a patient who is participating in other clinical trials will be dealt with on a case by case basis. 5. Treatment with immunomodulator or immunosuppressant drugs, including but not limited to IL-6 inhibitors, TNF inhibitors, antiIL-1 agents, and JAK inhibitors within 5 half-lives or 30 days (whichever is longer) before randomization. (Note treatment with immunomodulator or immunosuppressant drugs, such as corticosteroids, as part of SOC, is permitted). 6. Known other clinical conditions that contraindicate EB05 and cannot be treated or solved according to the judgement of the clinician.